Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Indivior Pharmaceuticals Inc (INDV)

Indivior Pharmaceuticals Inc (INDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,431,959
  • Shares Outstanding, K 125,020
  • Annual Sales, $ 1,188 M
  • Annual Income, $ 2,000 K
  • EBIT $ 277 M
  • EBITDA $ 306 M
  • 60-Month Beta 0.80
  • Price/Sales 3.84
  • Price/Cash Flow 19.23
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 65.25% (-0.08%)
  • Historical Volatility 24.47%
  • IV Percentile 40%
  • IV Rank 25.94%
  • IV High 186.83% on 02/19/25
  • IV Low 22.67% on 09/05/25
  • Expected Move (DTE 16) 3.53 (10.26%)
  • Put/Call Vol Ratio 1.47
  • Today's Volume 94
  • Volume Avg (30-Day) 267
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 22,191
  • Open Int (30-Day) 22,997
  • Expected Range 30.84 to 37.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.65
  • Number of Estimates 3
  • High Estimate 0.72
  • Low Estimate 0.53
  • Prior Year 0.32
  • Growth Rate Est. (year over year) +103.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.70 +9.15%
on 01/20/26
37.66 -8.13%
on 01/08/26
-1.13 (-3.16%)
since 01/02/26
3-Month
29.39 +17.73%
on 11/14/25
38.00 -8.95%
on 12/08/25
+2.60 (+8.12%)
since 11/04/25
52-Week
7.62 +354.07%
on 02/25/25
38.00 -8.95%
on 12/08/25
+23.20 (+203.51%)
since 02/04/25

Most Recent Stories

More News
S&P 500, MidCap 400, and SmallCap 600 Welcome New Members as Indexes Rebalance for 2026

The S&P 500’s latest rebalance reveals how the index quietly upgrades itself by promoting winners like Carvana and CRH and removing underperformers through a process that more closely resembles disciplined...

APP : 387.18 (-16.16%)
ENPH : 51.53 (+38.22%)
PRIM : 147.25 (-5.02%)
HL : 22.70 (-3.16%)
SOLS : 65.51 (-1.13%)
MKTX : 162.05 (+1.10%)
CHAR : 10.53 (-0.14%)
CWST : 104.26 (+1.05%)
UA : 6.55 (+6.85%)
BWA : 50.49 (+3.95%)
PRGO : 14.77 (+4.46%)
IRDM : 19.50 (-0.61%)
Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher

Virginia-based Indivior, a developer of opioid addiction treatments, continues to hold down a place in Barchart’s Top 100 Stocks to Buy. Up 192% in 2025, its P/E is declining despite the stock’s gains...

INDV : 34.56 (-2.51%)
Indivior Announces Inclusion in the S&P SmallCap 600® Index

RICHMOND, Va. , Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) (" Indivior PLC " or the " Company ") today announced that it will be added to the S&P SmallCap 600 ® index,...

INDV : 34.56 (-2.51%)
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

RICHMOND, Va. , Dec. 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in  JAMA Network Open.  The...

INDV : 34.56 (-2.51%)
CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK , Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open...

PRIM : 147.25 (-5.02%)
HL : 22.70 (-3.16%)
SOLS : 65.51 (-1.13%)
CWST : 104.26 (+1.05%)
UA : 6.55 (+6.85%)
BWA : 50.49 (+3.95%)
PRGO : 14.77 (+4.46%)
IRDM : 19.50 (-0.61%)
MHK : 130.39 (+4.52%)
CEVA : 20.86 (+0.77%)
INDV : 34.56 (-2.51%)
DY : 362.34 (-7.50%)
Indivior Concludes Legacy U.S. Department of Justice Matter

RICHMOND, Va. , Nov. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding...

INDV : 34.56 (-2.51%)
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

RICHMOND, Va. , Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37 th Annual Healthcare Conference:

INDV : 34.56 (-2.51%)
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

RICHMOND, Va. , Nov. 3, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week,...

INDV : 34.56 (-2.51%)
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

RICHMOND, Va. , Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

INDV : 34.56 (-2.51%)
Indivior to Participate in the Stifel 2025 Healthcare Conference

RICHMOND, Va. , Oct. 28, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference:

INDV : 34.56 (-2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine...

See More

Key Turning Points

3rd Resistance Point 36.85
2nd Resistance Point 36.20
1st Resistance Point 35.83
Last Price 34.56
1st Support Level 34.81
2nd Support Level 34.16
3rd Support Level 33.79

See More

52-Week High 38.00
Last Price 34.56
Fibonacci 61.8% 26.39
Fibonacci 50% 22.81
Fibonacci 38.2% 19.23
52-Week Low 7.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar